All In Biotech

Drug Trial Radar · NCT05566041

A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer

REPLATINUM: A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 Administered Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Oct 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 292 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

292

Planned (sponsor's estimate)

Start

Aug 1, 2022

Primary completion

Dec 31, 2025

Study completion Dec 31, 2025

Sponsor

Lead sponsor
EpicentRx, Inc.Industry
Sponsor type
Industry
Collaborators
Sciclone Pharmaceuticals (China) Co., Ltd.
First posted
Oct 4, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Global Phase 3 study aims to find out whether RRx-001 + platinum chemotherapy is more effective than platinum chemotherapy alone in 3rd line or beyond small cell cancer.

Conditions

  • Carcinoma, Small Cell Lung

Interventions

  • RRx-001 + eLOOP DeviceDrug

    RRx-001 is a small molecule anticancer drug which is mixed with patient's own blood using the eLOOP device Drug: Cisplatin/carboplatin plus etoposide Standard of care platinum doublet chemotherapy

  • Cisplatin/carboplatin plus etoposideDrug

    Standard of care platinum doublet chemotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) and Overall Survival (OS)Time frame: Estimated up to 12 Months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • H. Lee Moffitt Cancer Center & Research Institute, Inc.

    Tampa, Florida

  • The University of Kansas Cancer Center

    Westwood, Kansas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.